AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00638872 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polydeoxyribonucleotide
Description: 3 times a week perilesional or intramuscular injections
Study NCT00638872 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% NaCl
Description: same as PDRN
Study NCT04298411 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Falcon
Description: The Falcon contains a selection of 25+ games that require wrist extension and challenges children to grasp the controller with their affected hand. As children progress, they may advance to more difficult games that challenge the child to work against a resistance and/or apply greater grip forces. Therapists will be trained on the system, games, and given a guide summarizing the available games and the motor function areas targeted in the game. Using this guide, therapists can choose the games that are most suited to the child's abilities and goals. As multiple games will target many of the same motor function areas, children will have the option of choosing the games they like best to maximize motivational value. While this introduces some variability in the intervention, this flexibility is required to ensure that the therapy is targeting the specific interests, needs and goals of each individual child and is reflective of how ICP is used in a clinic setting.
Study NCT02432807 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin 1.1%
Description: Vancomycin hydrochloride ophthalmic ointment 1.1%
Study NCT02432807 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02560766 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HORIZANT 300 mg
Description: HORIZANT 300 mg once daily
Study NCT02079727 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chondroitin sulfate
Study NCT02079727 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: celecoxib
Study NCT02079727 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT03023748 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous Paricalcitol
Description: Twenty four months of intravenous paricalcitol will be given twice or thrice weekly post-hemodialysis depending on frequency of hemodialysis of the patients
Study NCT00384956 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Study NCT04398901 — intervention group
Intervention type: OTHER
Intervention: Neurodevelopmental assessments
Description: The investigators will evaluate multiple domains of neurodevelopment at age 3, 4, 5 and 7 years using parental questionnaires and child exams. At age 7 years, the children will have a non-sedated quantitative brain MRI.
Study NCT02560766 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HORIZANT 600 mg
Description: HORIZANT 600 mg once daily
Study NCT02560766 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo once daily
Study NCT02397837 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pramipexole
Description: Up to 4.5mg, PO, (by mouth) per day of the 12-week study.
Study NCT02397837 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo match study drug
Study NCT01002105 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baclofen
Description: Baclofen 50mg per day for 12 weeks and psychosocial intervention
Study NCT01002105 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control group
Description: psychosocial intervention and placebo for 12 weeks
Study NCT05791110 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Fecal pancreatic elastase 1 test
Description: Fecal pancreatic elastase 1 test are immunoassays for the quantitative determination of fecal pancreatic elastase in human stool samples.
Study NCT02953093 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: See arm description
Study NCT02746081 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1436032
Description: The selected starting dose of BAY1436032 is 300 mg/day (150 mg BID) to be administered orally continuously in tablet form in 21-day cycles. Adjustments to this schedule may be made if warranted by information collected during the course of the study. The maximum feasible dose of BAY1436032 is expected to be 3000 mg/day.
Study NCT02653014 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KBP-5074
Study NCT00398398 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine, Oxaliplatin, Cetuximab
Description: Xelox(Capecitbine, Oxaliplatin) and Cetuximab every three week; Capecitabine 1,000 mg/m2 was administered twice daily on days 1-14. Oxaliplatin 130 mg/m2 i.v. for 2 h was given on day 1 after cetuximab infusion. Cetuximab at an initial loading dose of 400 mg/m2 i.v. for 2 h and, thereafter, maintenance dose of 250 mg/m2 for 1 h every week.
Study NCT00895973 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stirrups delivery vs bed delivery
Description: Position of legs at time of vaginal delivery (bed vs stirrups)
Study NCT00696085 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Brief motivational intervention
Description: The women who have positive alcohol screening questionnaires and a random sample of women who screen negative are entered into the next phase of the study. They have blood drawn for the markers of alcohol use, are told of the results and are given brief intervention about alcohol use.
Study NCT02169895 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 9-1067
Study NCT02169895 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BIA 9-1067
Study NCT02169895 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT02169895 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Study NCT02169895 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prolopa®
Description: levodopa/benserazide 100/25 mg
Study NCT01702116 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: extralevator APR
Description: Extralevator Abdominoperineal Resection For Rectal Adenocarcinoma. The aim of this modified and more extensive procedure is to remove the levator muscle en bloc with the anal canal and the mesorectum, creating a more cylindrical specimen, so that the amount of tissue removed around the tumor will be larger, thereby reducing the probability that the CRM will be positive.
Study NCT02169895 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prolopa®
Description: levodopa/benserazide 100/25 mg
Study NCT01295346 — intervention group
Intervention type: OTHER
Intervention: Head CT scan and blood draw
Study NCT04240756 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral Parent Training
Description: Parents will receive 10 sessions of behavioral parent training with components specifically targeted toward parents with ADHD. Treatment will be delivered via telehealth.
Study NCT01702116 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: APR
Description: standard Abdominoperineal Resection For Rectal Adenocarcinoma
Study NCT02760251 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: romiplostim
Study NCT03492164 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: [18F]FluorThanatrace ([18F]FTT)
Description: 1-(4-(2-Fluoroethoxy)phenyl)-8,9-dihiydro-2,7,9a-triazabenzo\[cd\]azulen-6(7H)-one also known as \[18F\]FluorThanatrace or \[18F\]FTT is a positron emitting radiopharmaceutical that has been studied in animals for selective measurement of the in vivo inhibition of the PARP-1 nuclear enzyme with positron emission tomography (PET/CT).
Study NCT01689558 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombine Endostatin
Description: Recombine Endostatin is involved in the arm of Recombine Endostatin .Recombinant human vascular endothelial inhibin 7.5 mg/M2 / d dose add 250 ml of physiological saline, dilute in new adjuvant chemotherapy began to 8-21 days intravenous drip, at least 1 hour, a total of 1 cycle; The chemoradiation in cisplatin chemotherapy first day grace degrees 7.5 mg/M2 / d, 1-14 days, a total of one period of treatment
Study NCT04665232 — intervention group
Intervention type: DRUG
Intervention: aqueous subcutaneous progesterone
Description: 25 mg/die of aqueous subcutaneous progesterone from the day of oocytes retrieval for two weeks.
Study NCT02665936 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levobupivacaine
Description: Levobupivacaine will be given epidurally and the duration of analgesia will be calculated
Study NCT02665936 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone and levobupivacaine
Description: dexamethasone 4 mg epidurally with levobupivacaine and duration of analgesia is measured
Study NCT02665936 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levobupivacaine and Dexamethasone
Description: dexamethasone 8 mg epidurally with levobupivacaine and duration of analgesia is measured
Study NCT04753112 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacubitril / Valsartan Oral Tablet [Entresto]
Description: Treatment of Pulmonary Hypertension With Angiotensin II Receptor Blocker and Neprilysin Inhibitor
Study NCT00364793 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efavirenz (EFV) + Didanosine (ddI) + Emtricitabine (FTC)
Description: Oral Solution, Capsules or Tablets, Oral, once daily~Efavirenz (EFV) per weight-based dosing nomogram (max 720 mg)~Didanosine (ddI) 240 mg/m2 (max 400 mg)~Emtricitabine (FTC) 6 mg/kg (max 200 mg)~Where EFV oral solution is commercially available: 48 weeks or until 3rd birthday (whichever is longer);~Where EFV oral solution NOT commercially available: until 7th birthday or until able to swallow EFV capsules (whichever occurs first)
Study NCT03421548 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EyeMate
Description: Patients will undergo implantation BKPro with concomitant implantation of the EyeMate pressure sensor. The surgical approach will involve a trephination of the central recipient cornea of adequate size. In subjects with adequate capsular support, the sensor device will be placed in the sulcus space by grasping the sensor's silicone sleeve at approximately the 3 and 9 o'clock positions and sliding it into the sulcus space. In subjects in whom capsular support is inadequate, the Eyemate implant will be sutured to the sclera. This is performed by placing an 8-O Gortex suture or 9-O prolene on CIF-4 needles around the antenna at the 2 and 7 o'clock positions and suturing the device to the sclera using an ab-interno technique.
Study NCT01451515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given orally (PO).
Study NCT01451515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Given intravenously (IV).
Study NCT01451515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin
Description: Given IV.
Study NCT01451515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-asparaginase
Description: Given intramuscularly (IM) or IV.
Study NCT01451515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erwinia asparaginase
Description: Given IM or IV if allergy occurs with the first or second PEG-asparaginase dose.
Study NCT01451515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Given IV.
Study NCT01451515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV.
Study NCT01451515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV or IT.
Study NCT01451515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thioguanine
Description: Given PO.
Study NCT01451515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofarabine
Description: Given IV.
Study NCT01451515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given IV, IM or IT.
Study NCT01451515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mercaptopurine
Description: Given PO.
Study NCT01451515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO or IV.
Study NCT01451515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Description: Given IT.
Study NCT01451515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV.
Study NCT01646710 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pretesting food based recommendations
Study NCT01563601 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obatoclax Mesylate, Carboplatine and Etoposide
Description: Obatoclax Mesylate:~30 mg fixed dose;administered IV on days 1-3 every 21 days for 6 cycles. Maintenance therapy (optional and only if documented CR or PR) with obatoclax mesylate is administered at the same IV dose on days 1-3 every 21 days until disease progression or death.~Carboplatin:~Dose targeted at AUC of 5; administered IV on Day 1 only every 21 days for 6 cycles~Etoposide:~100mg/m2 administered IV on Days 1-3 every 21days for 6 cycles
Study NCT01563601 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin and Etoposide
Description: Carboplatin:~Dose targeted at AUC of 5 administered IV on Day 1 only every 21 days for 6 cycles.~Etoposide:~100mg/m2 administered IV on Days 1-3 every 21 days for 6 cycles
Study NCT00775021 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: etafilcon A
Description: Contact Lens
Study NCT00775021 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: nelfilcon A
Description: Contact Lens
Study NCT00685282 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Cognitive Behavioral Therapy
Description: The intervention (CBT) will focus on teaching specific skills which are adapted for women undergoing fertility related problems. Through the sessions the participants will learn relaxation techniques such as breathing, progressive relaxation, and guided imagery. Furthermore, suggestions for making healthier choices for coping and for releasing tension will be reviewed and discussed, with an emphasis on making healthy lifestyle changes with balance and perspective rather than in a punishing or depriving way. Each session will consist of: 20 minutes of stress-reduction behavioral relaxation, 40 minutes of cognitive restructuring and 30 minutes personal tailoring of the behavioral homework between each session.
Study NCT03464838 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation (tDCS)
Description: Transcranial direct current stimulation (tDCS) is a form of noninvasive brain stimulation that applies a very low electrical current to the scalp. tDCS will be applied with intensity of 1.8 milliamps in real stimulation condition and 0 milliamps in sham condition, during 20 minutes, using a high density (HD) tDCS montage over the Prefrontal Cortex (PFC). Electroencephalography (EEG) resting state activity will be measured before and after tDCS.
Study NCT03464838 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial direct current stimulation (tDCS)
Description: Transcranial direct current stimulation (tDCS) is a form of noninvasive brain stimulation that applies a very low electrical current to the scalp. tDCS will be applied with intensity of 1.8 milliamps in real stimulation condition and 0 milliamps in sham condition, during 20 minutes, using a high density (HD) tDCS montage over the Prefrontal Cortex (PFC). Electroencephalography (EEG) resting state activity will be measured before and after tDCS.
Study NCT03464838 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy (CBT)
Description: Cognitive Behavioural Therapy (CBT) is the current treatment available for disordered gamblers at the UK National Problem Gambling Clinic. During the therapy sessions patients acquire learning strategies, cognitive and motivational elements, and develop personal skills to help them improve the understanding of their problems.
Study NCT03464838 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Cognitive Behavioural Therapy (CBT)
Description: Cognitive Behavioural Therapy (CBT) is the current treatment available for disordered gamblers at the UK National Problem Gambling Clinic. During the therapy sessions patients acquire learning strategies, cognitive and motivational elements, and develop personal skills to help them improve the understanding of their problems.
Study NCT00818272 — intervention group
Intervention type: BIOLOGICAL
Intervention: Remicade (infliximab)
Description: Participants with confirmed diagnosis of severe active Crohn's disease (CD) and participants suffering from fistulae who do not respond sufficiently to a complete and adequate therapy with a conventional treatment received infliximab administration as intravenous (IV) infusion over a period of two hours. Dosage and infusion intervals were employed in accordance to the Summary of Product Characteristics (SmPC): 5 mg/kg body weight at week 0 of infliximab therapy with additional infusions of 5 mg/kg at week 2 and week 6 after the initial dose, followed by infusions every 8 weeks (maintenance) or if signs and symptoms of the disease recur (readministration).
Study NCT01175720 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Periodontal surgery to gingival recessions
Description: Test and control technique to treat gingival recessions.
Study NCT06417515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xiao-Yao-San
Description: Patients who received Xiao-Yao-San 9 g/day (Kaiser Pharmaceutical Co. Ltd.) were selected for the Xiao-Yao-San group by traditional Chinese doctor with 8 years of experience.
Study NCT06417515 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Weight loss class(WLC) group
Description: Participants who attended the WLCs in our hospital and were willing to participate in our study were included in the WLC group (control group). Our WLCs consisted of 8 sessions of 2-hour dietary advice/exercise guidance and 1 session of weight-loss consultation in 3 months. The participants assessed their weights at the beginning, at 1.5 months, and after every class. They underwent pre-PSG tests in the beginning and post-PSG tests after 3 months of lectures.
Study NCT00442598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glufosfamide
Study NCT00359892 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obatoclax mesylate (GX15-070MS)
Description: 60 mg q2wks
Study NCT01962220 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Study Intervention for Retention (APFU)
Description: Each newly identified HIV-infected pregnant woman randomized to the experimental arm will be assigned an outreach worker/counselor (Mama Mshauri).~Mama Mshauri tasks will include:~* Immediately engaging the newly identified pregnant woman, providing individualized adherence and disclosure support, management of ART side effects, and helping the client navigate the health system.~* Providing tailored individualized health education during home visits.~Additional intervention components include:~* Appointments and Reminders: SMS or telephone reminders 1 week and 3 days before appointments. Reinforcement of importance of follow-up during home visits and every contact.~* Patient Tracking and Defaulter Tracing: Monthly visits and immediate calls/home visit if she misses an appointment.
Study NCT04076826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Dexmedetomidine infusion will be commenced in accordance with the hospital's local sedation protocol, without a loading dose, at a rate of 0.1 - 1.4 mcg/kg/hour to maintain sedation as per Richmond Agitation-Sedation Scale (RASS) sedation range specified by the treating clinician. Infusion will be continued until sedation is no longer clinically indicated up to a maximum of 7 days after enrolment.
Study NCT04076826 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol or Midazolam
Description: Propofol and/or Midazolam will be used according to Hospital guidelines to maintain sedation as per Richmond Agitation-Sedation Scale (RASS) sedation range specified by the treating clinician.
Study NCT04076826 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: In all participants, we will collect blood samples for measurement of neuronal and systemic biomarkers of inflammation at randomization (baseline), at day 1, day 2 and day 3 after randomization.
Study NCT04076826 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Blood sampling
Description: In all participants, we will collect blood samples for measurement of neuronal and systemic biomarkers of inflammation at randomization (baseline), at day 1, day 2 and day 3 after randomization.
Study NCT01974323 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapsone Gel
Description: Dapsone gel applied topically to the face and to affected areas of the trunk once daily for 12 weeks.
Study NCT01974323 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dapsone Gel Vehicle
Description: Dapsone gel vehicle applied topically to the face and to affected areas of the trunk once daily for 12 weeks.
Study NCT01926587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral rigosertib
Description: Oral rigosertib will be administered twice a day in fasting conditions for weeks 1, 2, and 3 of a 4-week cycle.
Study NCT01926587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Starting on Day 1 of second week (Day 8) of the cycle, azacitidine will be administered by subcutaneous injection or intravenous infusion at the labeled daily dose of 75 mg/m2, for 7 days.